CStone Announces Promising NSCLC Treatment Data

CStone Pharmaceuticals (HK:2616) has released an update.

CStone Pharmaceuticals has reported positive long-term survival data for Cejemly (sugemalimab) used with platinum-based chemotherapy as a first-line treatment for advanced-stage non-small cell lung cancer (NSCLC) at the ESMO 2024 Annual Meeting. The company highlights a four-year survival rate of 32.1% for patients treated with sugemalimab, as well as significant improvement in progression-free survival (PFS) and overall survival (OS) across various patient subgroups. These results reinforce Cejemly’s potential to become a preferred immunotherapy option for NSCLC, including for those with brain metastases.

For further insights into HK:2616 stock, check out TipRanks’ Stock Analysis page.